Anti CCR2 monoclonal antibody

Drug Profile

Anti CCR2 monoclonal antibody

Latest Information Update: 20 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Coronary artery restenosis; Vascular restenosis

Most Recent Events

  • 20 Jul 2006 Discontinued - Preclinical for Coronary artery restenosis in USA (unspecified route)
  • 20 Jul 2006 Discontinued - Preclinical for Vascular restenosis in USA (unspecified route)
  • 21 Nov 2001 Preclinical development for Coronary artery restenosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top